Gastroparesis Market Report 2025

The gastroparesis market size has grown steadily in recent years. It will grow from $6.84 billion in 2024 to $7.17 billion in 2025 at a compound annual growth rate (CAGR) of 4.9%. The growth in the historic period can be attributed to aging population, increasing prevalence of diabetes, improved understanding of gastrointestinal disorders, evolving treatment protocols, growing awareness about gastroparesis.

The gastroparesis market size is expected to see strong growth in the next few years. It will grow to $8.82 billion in 2029 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to development of novel therapeutic options, expansion of personalized medicine approaches, integration of digital health solutions, rise in healthcare infrastructure, increasing focus on early diagnosis. Major trends in the forecast period include advancements in gastric electrical stimulation therapy, growing research in stem cell therapy, adoption of minimally invasive surgical interventions, increased use of wearable health monitoring devices, focus on patient-centric care models.

The anticipated growth in healthcare expenditure is expected to drive the expansion of the gastroparesis market in the coming years. Healthcare expenditure encompasses the total resources allocated to health services, including costs associated with hospitals, medical professionals, nursing, dental care, medications, and public health initiatives. Factors such as an aging population, advancements in medical technology, an increasing prevalence of chronic diseases, and heightened consumer expectations for enhanced healthcare services contribute to the rise in healthcare spending. This increase benefits the gastroparesis market by providing additional financial support for research and development, broadening treatment options, and improving patient access to specialized healthcare services. For instance, a report from the Office for National Statistics, a UK-based government department, indicated that healthcare spending in the UK rose by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. In 2023, the UK's healthcare expenditure reached approximately $317.63 billion (£292 billion). Thus, the growth in healthcare expenditure is propelling the gastroparesis market.

The rapid increase in diabetes prevalence is projected to drive the growth of the gastroparesis market in the future. Diabetes is a chronic medical condition characterized by elevated blood glucose levels due to the body's inability to produce sufficient insulin or utilize the insulin it does produce effectively. The rise in diabetes cases significantly heightens the risk of developing gastroparesis, as diabetes is a key factor contributing to the at-risk population for this condition. For example, data from the Australian Bureau of Statistics, an Australian government agency, revealed that in 2022, 5.3% of the Australian population (approximately 1.3 million individuals) had diabetes, a significant increase from 3.3% in previous years. Consequently, the rapid surge in diabetes prevalence is fueling the growth of the gastroparesis market.

The anticipated growth of the gastroparesis market is expected to be driven by the increasing proportion of aging individuals. Aging individuals refer to those who are advancing in age or undergoing the aging process. The aging population significantly impacts the gastroparesis market due to an elevated prevalence among older individuals, associations with age-related conditions, and distinctive challenges in diagnosing and managing gastroparesis in the elderly. For example, in June 2023, the United States Census Bureau, a US-based government agency, reported a 0.2-year increase in the country's median age to 38.9 years in 2022 from 2021 to 2022, indicating a continued aging trend in the population. Hence, the growing proportion of aging individuals is propelling the gastroparesis market.

Major companies in the gastroparesis market are investing in innovative devices to enhance their market position and profitability. Devices designed for gastroparesis treatment are medical tools or equipment aimed at managing or alleviating symptoms related to delayed stomach emptying. For instance, in 2022, Enterra Medical Inc., a US-based medical device company, introduced the Enterra Therapy for treating gastroparesis. The Enterra Therapy system utilizes an implanted neurostimulator to deliver gentle electrical pulses, offering potential relief for symptoms such as chronic nausea and vomiting associated with gastroparesis. This therapy is intended for individuals aged 18 to 70 experiencing chronic, intractable (drug-refractory) nausea and vomiting linked to gastroparesis of diabetic or idiopathic origin.

Major companies in the gastroparesis market are also developing drugs to bolster their profitability. Drugs used in gastroparesis treatment serve various purposes to address symptoms associated with delayed stomach emptying. For example, in December 2023, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, announced that the U.S. FDA had accepted the New Drug Application for Tradipitant. This development represents a significant step toward potential approval for treating gastroparesis, with the FDA setting the decision date for Tradipitant under the Prescription Drug User Fee Act (PDUFA) on September 18, 2024. If successful, Tradipitant would be the first FDA-approved novel drug for gastroparesis in over 40 years, marking a significant milestone in more than three decades for a drug specifically undergoing FDA review for gastroparesis.

Major companies operating in the gastroparesis market include Pfizer Inc., GlaxoSmithKline plc., Abbott Laboratories Inc., AstraZeneca Plc., Medtronic Plc., Takeda Pharmaceutical Company Limited, Johnson And Johnson Services Inc., Teva Pharmaceutical Industries Ltd, AbbVie Inc., Boston Scientific Corporation, Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Daewoong Pharmaceutical co. ltd, ReGenXBio Inc., ANI Pharmaceuticals Inc., Dompe Farmaceutici S.p.A, Sucampo Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Theravance Biopharma Inc., RedHill Biopharma Ltd., Valeant Pharmaceuticals International Inc., CinRx Pharma LLC., Ritter Pharmaceuticals Inc., Evoke Pharma Inc., Metacrine Inc., Neurogastrx Inc.

North America was the largest region in the gastroparesis market in 2024. The regions covered in the gastroparesis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gastroparesis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Gastroparesis is a medical condition characterized by the impairment or weakening of the stomach muscles, leading to the delayed emptying of stomach contents into the small intestine. The treatment of gastroparesis involves medications aimed at stimulating stomach emptying, managing underlying conditions, and surgical interventions.

The primary treatment modalities for gastroparesis include medications, dietary modifications, medical devices, and other approaches. Medications are substances that interact with the body's biological processes to produce a desired effect. Prokinetic drugs, antiemetics, botulinum toxin injections, antidepressants, and other medications are utilized to diagnose, treat, cure, or prevent gastroparesis. These medications are employed in the treatment of various types of gastroparesis, including idiopathic, diabetic, post-surgical, and others, in both pediatric and adult patients. They are distributed through retail pharmacies, hospital pharmacies, and other channels, making them accessible to hospitals and clinics, ambulatory surgical centers, and home care settings.

The gastroparesis research report is one of a series of new reports that provides gastroparesis market statistics, including the gastroparesis industry's global market size, regional shares, competitors with gastroparesis market share, detailed gastroparesis market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis industry. This gastroparesis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastroparesis market consists of sales of metoclopramide, domperidone, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.